Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
Heart Failure
Effect of Carvedilol on Plasma Adiponectin Concentration in Patients With Chronic Heart Failure
Masayuki YamajiTakayoshi TsutamotoToshinari TanakaChiho KawaharaKeizo NishiyamaTakashi YamamotoMasanori FujiiMinoru Horie
Author information

2009 Volume 73 Issue 6 Pages 1067-1073


Background: Patients with a high plasma adiponectin have a poor prognosis in chronic heart failure (CHF). Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are reported to increase the plasma adiponectin concentration, but the effect of β-blockers on plasma adiponectin in patients with CHF remains unknown. Methods and Results: Blood samples were collected at before and 6 months after administration of carvedilol in 44 CHF patients. The hemodynamic parameters, echocardiography, plasma concentrations of brain natriuretic peptide (BNP), norepinephrine and adiponectin were measured. Six months after treatment, there were significantly decreased plasma concentrations of adiponectin (15.8 ±1.4 to 11.0 ±1.1 μg/ml, P<0.0001), BNP and norepinephrine and increased left ventricular ejection fraction (LVEF). On stepwise multivariable analyses, a higher plasma adiponectin concentration before treatment (rs=-0.561, P<0.0001) was a significant independent predictor of a greater decrease in adiponectin concentration and the decrease in plasma adiponectin concentration was significantly correlated with the improvement of LVEF (r=-0.561, P<0.0001). Conclusions: These findings indicate that carvedilol decreases plasma adiponectin concentration and that the decrease in plasma adiponectin is associated with the improvement of LVEF after treatment with carvedilol in CHF patients. (Circ J 2009; 73: 1067-1073)

Information related to the author
Previous article Next article